1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Compliance

Lab Owner, Test Kit Vendors Charged In COVID-19 Fraud Crackdown

 
• By Elizabeth Orr

The US Department of Justice has filed criminal charges against 18 individuals said to be responsible for a total of $490m in COVID-19 fraud, including several device- and diagnostic-related cases.

Eighteen individuals are facing criminal charges for their role in health care fraud schemes related to the COVID-19 pandemic, the US Department of Justice announced on 20 April. The fraud reportedly cost the government $490m in false billings and theft from pandemic programs.

In addition to the criminal charges, DOJ seized $16m in cash and other fraud proceeds.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.